Trial Profile

Efficacy of Sevikar Compared to the Combination of Perindopril/Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olmesartan medoxomil/amlodipine (Primary) ; Amlodipine; Hydrochlorothiazide; Perindopril
Indications Essential hypertension; Hypertension
Focus Therapeutic Use
Acronyms SEVITENSION
Sponsors Daiichi Sankyo Europe

Most Recent Events

23 Sep 2015 Results of a post hoc subgroup (diabetic patients) analysis published in the Journal of Clinical Hypertension (Greenwich).
25 Jun 2013 Primary endpoint 'Central-systolic-blood-pressure' has been met.
25 Jun 2013 First findings from this study were revealed at an ESH 2013 poster session, according to a Daiichi Sankyo media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com